Boston Scientific Corporation (NYSE:BSX) Given Consensus Rating of “Buy” by Brokerages

Boston Scientific Corporation (NYSE:BSX) has been given a consensus rating of “Buy” by the twenty-four research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, twenty have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $124.85.

Several research firms recently weighed in on BSX. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. The Goldman Sachs Group reissued a “buy” rating and set a $124.00 price target on shares of Boston Scientific in a research report on Wednesday, October 22nd. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Cowen reiterated a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Finally, Leerink Partners increased their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st.

Boston Scientific Stock Down 0.7%

Shares of Boston Scientific stock opened at $94.72 on Monday. The business has a fifty day simple moving average of $97.92 and a 200 day simple moving average of $100.91. The stock has a market cap of $140.42 billion, a PE ratio of 50.65, a price-to-earnings-growth ratio of 1.68 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific has a 12 month low of $85.98 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company’s revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts predict that Boston Scientific will post 2.85 EPS for the current year.

Insider Buying and Selling

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 93,095 shares of company stock valued at $9,305,450. 0.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Steph & Co. bought a new stake in shares of Boston Scientific in the third quarter valued at about $25,000. Financial Consulate Inc. acquired a new stake in Boston Scientific in the 3rd quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp lifted its stake in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares in the last quarter. 1248 Management LLC acquired a new position in Boston Scientific during the 1st quarter worth approximately $26,000. Finally, FWL Investment Management LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.